Vesikari, Dennehy et al
| Periods analyzed | Dose 1 to Dose 2 (95% CI) | Dose 2 to Dose 3 (95% CI) | ||
|---|---|---|---|---|
| G1–G4 Serotypes | Any Serotype | G1–G4 Serotypes | Any Serotype | |
| A: ⩾14 days PD1 to Dose 2 and ⩾14 days PD2 to Dose 3 | 100 (72–100) | 82 (39–97) | 91 (63–99) | 84 (54–96) |
| B: ⩾14 days PD1 to Dose 2 and Dose 2 to Dose 3 | Same as Analysis A | 95 (78–99) | 88 (68–96) | |
| C: ⩾14 days PD1 to 13 days PD2 and ⩾14 days PD2 to 13 days PD3 | 100 (87–100) | 88 (65–97) | 91 (72–98) | 88 (69–96) |